osimertinib
astrazeneca
['adaura', 'nsclc', 'sclc', 'osimertinib', 'aura ,(-laura)']
the adaura study has demonstrated a statistically significant and clinically meaningful os benefit with adjuvant osimertinib vs placebo in patients with resected egfrm stage ib-ia nsclc #asco2023 #asco23 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.